JP2017535258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535258A5 JP2017535258A5 JP2017519646A JP2017519646A JP2017535258A5 JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5 JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5
- Authority
- JP
- Japan
- Prior art keywords
- site
- exogenous
- goi
- nucleic acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 230000006798 recombination Effects 0.000 claims description 26
- 238000005215 recombination Methods 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 102000018120 Recombinases Human genes 0.000 claims description 16
- 108010091086 Recombinases Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 12
- 101710163270 Nuclease Proteins 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 238000010459 TALEN Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 4
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 102100034343 Integrase Human genes 0.000 claims description 3
- 108010061833 Integrases Proteins 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 102000008579 Transposases Human genes 0.000 claims description 3
- 108010020764 Transposases Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067774P | 2014-10-23 | 2014-10-23 | |
| US62/067,774 | 2014-10-23 | ||
| PCT/US2015/056653 WO2016064999A1 (en) | 2014-10-23 | 2015-10-21 | Novel cho integration sites and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535258A JP2017535258A (ja) | 2017-11-30 |
| JP2017535258A5 true JP2017535258A5 (enExample) | 2018-11-22 |
| JP6668340B2 JP6668340B2 (ja) | 2020-03-18 |
Family
ID=54602002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519646A Active JP6668340B2 (ja) | 2014-10-23 | 2015-10-21 | 新規ｃｈｏ組込み部位およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9816110B2 (enExample) |
| EP (1) | EP3209785B1 (enExample) |
| JP (1) | JP6668340B2 (enExample) |
| KR (1) | KR102243243B1 (enExample) |
| CN (1) | CN107109434A (enExample) |
| AR (1) | AR102420A1 (enExample) |
| AU (1) | AU2015335921B2 (enExample) |
| BR (1) | BR112017008022A2 (enExample) |
| CA (1) | CA2965495C (enExample) |
| EA (1) | EA037255B1 (enExample) |
| IL (1) | IL251674B (enExample) |
| MX (1) | MX2017005306A (enExample) |
| MY (1) | MY184103A (enExample) |
| SG (1) | SG11201703149RA (enExample) |
| TW (2) | TWI747808B (enExample) |
| WO (1) | WO2016064999A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3209785B1 (en) | 2014-10-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Novel cho integration sites and uses thereof |
| US10329594B1 (en) | 2015-09-03 | 2019-06-25 | CHO Plus, Inc. | Cell lines for high level production of protein-based pharmaceuticals |
| US11649449B2 (en) | 2015-09-03 | 2023-05-16 | CHO Plus, Inc. | Hybrid cell lines for high level production of a target protein |
| US11512144B2 (en) | 2016-04-20 | 2022-11-29 | Regeneran Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing loci |
| IL262268B2 (en) * | 2016-04-20 | 2024-05-01 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| EP3559236A4 (en) * | 2016-12-20 | 2020-11-04 | Development Center for Biotechnology | TARGETED INTEGRATION SITES IN THE CHINESE HAMSTER OVARIAN CELL GENOME |
| US20210309988A1 (en) * | 2017-02-07 | 2021-10-07 | Sigma-Aldrich Co. Llc | Stable targeted integration |
| EP3583205A1 (en) * | 2017-02-17 | 2019-12-25 | Lonza Ltd | Mammalian cells for producing adeno-associated viruses |
| EP3601542A4 (en) * | 2017-03-19 | 2021-01-13 | Applied Stemcell, Inc. | NEW INTEGRATION SITES AND THEIR USES |
| JP7087061B2 (ja) * | 2017-08-11 | 2022-06-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｈｏ細胞内の組込み部位 |
| CN107723276B (zh) * | 2017-11-02 | 2021-08-13 | 上海交通大学 | 一种稳定高表达目标产物的细胞株的构建方法和试剂盒 |
| CN111566208A (zh) * | 2017-12-22 | 2020-08-21 | 生物辐射实验室股份有限公司 | 利用CRISPR/Cas基因靶向控制生物体表型 |
| TW201932600A (zh) * | 2017-12-22 | 2019-08-16 | 美商建南德克公司 | 核酸之靶向整合 |
| CN109321604B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用 |
| CN109337927B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用 |
| CN109295092B (zh) * | 2018-10-30 | 2021-06-29 | 江南大学 | 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用 |
| CN109295093B (zh) * | 2018-10-30 | 2021-08-03 | 江南大学 | 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用 |
| CN109207432B (zh) * | 2018-10-30 | 2021-08-03 | 江南大学 | 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用 |
| CN109136193B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用 |
| KR20210107057A (ko) * | 2018-12-21 | 2021-08-31 | 제넨테크, 인크. | 핵산의 표적화 통합 |
| IL286630B2 (en) * | 2019-04-02 | 2025-05-01 | Chugai Pharmaceutical Co Ltd | Method for introducing a target-specific foreign gene |
| CN114080454A (zh) | 2019-06-26 | 2022-02-22 | 豪夫迈·罗氏有限公司 | 核酸的随机化构型靶向整合 |
| EP3901266A1 (en) * | 2020-04-22 | 2021-10-27 | LEK Pharmaceuticals d.d. | Super-enhancers for recombinant gene expression in cho cells |
| EP4158041A4 (en) * | 2020-06-02 | 2024-09-25 | Catalent Pharma Solutions, LLC | CELL LINES WITH MULTIPLE DOCKING ZONES FOR GENE INSERTION |
| TW202216991A (zh) * | 2020-06-24 | 2022-05-01 | 美商建南德克公司 | 核酸之靶向整合 |
| IL302046A (en) | 2020-10-15 | 2023-06-01 | Hoffmann La Roche | Nucleic acid structures for va RNA transcription |
| CN113755447B (zh) * | 2021-09-23 | 2022-04-29 | 云舟生物科技(广州)股份有限公司 | 一种用于生产腺病毒的293a细胞株及其制备与应用 |
| KR20240099242A (ko) | 2021-10-18 | 2024-06-28 | 리제너론 파마슈티칼스 인코포레이티드 | 안정적인 통합 부위를 생산하기 위한 통합된 cas9 유전자를 포함하는 포유동물 세포, 및 안정적인 통합 부위 및 기타 부위를 포함하는 포유동물 세포 |
| MX2024004647A (es) | 2021-10-18 | 2024-05-02 | Regeneron Pharma | Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. |
| KR20240101596A (ko) | 2021-10-18 | 2024-07-02 | 리제너론 파마슈티칼스 인코포레이티드 | 폴리뉴클레오티드의 제어된 전사 |
| WO2023147462A2 (en) * | 2022-01-28 | 2023-08-03 | The Trustees Of Columbia University In The City Of New York | Genetic modifications for xenotransplantation |
| CN117305334B (zh) * | 2022-06-21 | 2024-11-08 | 深圳太力生物技术有限责任公司 | 靶向整合细胞及其制备方法、生产目标基因表达产物的方法 |
| WO2024107451A1 (en) | 2022-11-18 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Methods for detecting and evaluating viruses and virus-like particles |
| CN118726475B (zh) * | 2023-03-28 | 2025-07-08 | 深圳太力生物技术有限责任公司 | 核酸、重组载体、靶向整合细胞、基因表达方法和应用 |
| WO2024211287A1 (en) * | 2023-04-03 | 2024-10-10 | Seagen Inc. | Production cell lines with targeted integration sites |
| TW202528546A (zh) | 2023-09-07 | 2025-07-16 | 美商再生元醫藥公司 | 經共價表面修飾之腺相關病毒的生產及純化 |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| ATE539161T1 (de) | 1998-07-21 | 2012-01-15 | Millipore Corp | Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid |
| US6521419B1 (en) * | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| AU2002254529A1 (en) | 2001-04-04 | 2002-10-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Nucleic acids for transgene expression |
| US20040045043A1 (en) * | 2002-05-20 | 2004-03-04 | Finney Robert E. | Compositions and methods for generating conditional knockouts |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| ES2627552T3 (es) * | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| CN105969807A (zh) * | 2011-04-05 | 2016-09-28 | 斯克利普斯研究所 | 染色体着陆垫及相关用途 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP3683319A1 (en) * | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| CA2852955C (en) * | 2011-10-27 | 2021-02-16 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| CA2871524C (en) | 2012-05-07 | 2021-07-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| EP3209785B1 (en) | 2014-10-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Novel cho integration sites and uses thereof |
-
2015
- 2015-10-21 EP EP15797495.7A patent/EP3209785B1/en active Active
- 2015-10-21 EA EA201790698A patent/EA037255B1/ru unknown
- 2015-10-21 WO PCT/US2015/056653 patent/WO2016064999A1/en not_active Ceased
- 2015-10-21 CN CN201580069889.1A patent/CN107109434A/zh active Pending
- 2015-10-21 JP JP2017519646A patent/JP6668340B2/ja active Active
- 2015-10-21 BR BR112017008022-2A patent/BR112017008022A2/pt not_active Application Discontinuation
- 2015-10-21 MY MYPI2017701254A patent/MY184103A/en unknown
- 2015-10-21 CA CA2965495A patent/CA2965495C/en active Active
- 2015-10-21 SG SG11201703149RA patent/SG11201703149RA/en unknown
- 2015-10-21 US US14/919,300 patent/US9816110B2/en active Active
- 2015-10-21 AU AU2015335921A patent/AU2015335921B2/en active Active
- 2015-10-21 KR KR1020177012465A patent/KR102243243B1/ko active Active
- 2015-10-21 MX MX2017005306A patent/MX2017005306A/es unknown
- 2015-10-22 TW TW104134716A patent/TWI747808B/zh active
- 2015-10-22 TW TW110128495A patent/TWI780847B/zh active
- 2015-10-23 AR ARP150103445A patent/AR102420A1/es unknown
-
2017
- 2017-04-09 IL IL251674A patent/IL251674B/en active IP Right Grant
- 2017-10-13 US US15/783,525 patent/US20180030480A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/575,506 patent/US11788102B2/en active Active
-
2021
- 2021-02-12 US US17/175,025 patent/US11268109B2/en active Active
-
2023
- 2023-09-06 US US18/461,798 patent/US20240018553A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535258A5 (enExample) | ||
| JP7252328B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| KR102474757B1 (ko) | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 | |
| Massarwa et al. | WIP/WASp-based actin-polymerization machinery is essential for myoblast fusion in Drosophila | |
| Nozaki et al. | BBS1 is involved in retrograde trafficking of ciliary GPCRs in the context of the BBSome complex | |
| EP2627773B1 (en) | Restricted immunoglobulin heavy chain mice | |
| CN107090463A (zh) | 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法 | |
| JP2019514358A5 (enExample) | ||
| CN109195986B (zh) | 基于使用表达增强性基因座来制备抗体的组合物和方法 | |
| JP2017535258A (ja) | 新規ｃｈｏ組込み部位およびその使用 | |
| HRP20231707T1 (hr) | Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47 | |
| SA518391463B1 (ar) | VIII أشكال متباينة لعامل منخفضة تركيبات وطرق واستخدامات لمعالجة اضطرابات إرقاء الدم CpG، | |
| JP2015518479A5 (enExample) | ||
| JP2017514501A5 (enExample) | ||
| JP2016539629A5 (enExample) | ||
| KR20010024296A (ko) | 벡터 구조체와 세포 ｄｎａ의 비상동 재조합법에 의한내생 유전자 발현 | |
| JP2016513669A5 (enExample) | ||
| JP2011504721A5 (enExample) | ||
| KR20190063458A (ko) | Ｍｕｃ1에 특이적인 키메라 항원 수용체(ｃａｒｓ) 및 그의 사용 방법 | |
| JP2016526016A5 (enExample) | ||
| JP2019511918A5 (enExample) | ||
| JP6817944B2 (ja) | 最適化治療用分子を製造する方法 | |
| Rosenfeld et al. | A primer set for comprehensive amplification of V-genes from rhesus macaque origin based on repertoire sequencing | |
| CN115427558A (zh) | 用于高效且特异性基因组编辑的位点-特异性重组酶的融合物 | |
| JP2016540506A5 (enExample) |